

# Respiratory Disease in France



INTERNATIONAL  
RESPIRATORY  
COALITION

## Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

## Better...

1. Prevention of respiratory diseases
2. Access to the right treatment at the right time
3. Action on reducing inequalities
4. Prioritisation of research, data and insight to improve care

In the recently passed Social Security Financing Act for 2023, the French Health and Prevention Minister François Braun called upon parliament to vote in favor of preventive medical consultations at the ages of 25, 45 and 65 for every beneficiary of the Public Health Insurance. Further announcements on this act indicated that these consultations will include breath measurement.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders, including the French Respiratory Coalition, in promoting lung health across France by developing national strategies.

## Societal economic cost by disease:



Asthma  
€6.7 billion



COPD  
€11.7 billion



Lung Cancer  
€31.8 billion



Lower  
respiratory tract  
infections  
€7.7 billion



Mesothelioma  
€1.2 billion



Tuberculosis  
€446.5 million



Interstitial lung  
disease  
€2 billion



COVID-19  
€43.2 billion



Pulmonary arterial  
hypertension  
€226.0 million

144.6  
thousand  
deaths from respiratory  
diseases

8.1  
million  
people living with  
respiratory diseases

2.8  
million  
healthy life years lost to  
respiratory diseases

€104.9  
billion  
societal economic cost of  
respiratory diseases

This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.

Data taken from IRC Lung Facts <https://international-respiratory-coalition.org/lung-facts/diseases/>

January 2025